Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S6
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.
Seker-Cin H et al.
Lung Cancer (amsterdam, Netherlands), 2023
Development of a Cell Line Containing the Chimeric ETV6-NTRK3 Gene. The Search for Mutations of the Tyrosine Kinase Chimeric Domain That Cause Resistance to Larotrectinib.
Boyarskikh UA et al.
Bulletin of Experimental Biology and Medicine, 2023
Kinase inhibitors in thyroid cancers.
Sukrithan V et al.
Endocrine Oncology (bristol, England), 2023
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z et al.
Molecular Biomedicine, 2022
Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Dziadziuszko R et al.
Molecular Oncology, 2022
Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance.
Wang Z et al.
Journal of Medicinal Chemistry, 2022
Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib.
Wu WC et al.
Frontiers in Oncology, 2022
Molecular Characteristics of Repotrectinib That Enable Potent Inhibition of TRK Fusion Proteins and Resistant Mutations.
Murray BW et al.
Molecular Cancer Therapeutics, 2021
Mechanisms of targeted therapy resistance in a pediatric glioma driven by ETV6-NTRK3 fusion.
Keddy C et al.
Cold Spring Harbor Molecular Case Studies, 2021
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Somwar R et al.
Communications Biology, 2020
New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1).
Russo A et al.
Current Oncology Reports, 2020
Roles of TrkC Signaling in the Regulation of Tumorigenicity and Metastasis of Cancer.
Jin W
Cancers, 2020
Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion.
Chu QS
Therapeutic Advances in Medical Oncology, 2020
Select a paper to view details